Compare Gilead Sciences, Inc. (GILD) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Global X SuperDividend ETF — how do they compare? Gilead Sciences, Inc. trades at $134.63 (market cap $163.51B), while Global X SuperDividend ETF trades at $24.99. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while Global X SuperDividend ETF pays none. Which is the better fit depends on your goals.
| GILD | SDIV | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $155.80 | $26.34 |
52-Week Low | $108.22 | $22.90 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
